| PCWP <18 mmHg (n = 15) | PCWP ≥18 mmHg (n = 21) | p Value |
---|---|---|---|
Clinical data | Â | Â | Â |
Age | 57.7 ± 8.1 | 57.3 ± 8.6 | 0.77 |
Gender (% female) | 43.2 | 42.3 | 0.65 |
Body surface area (m2) | 1.95 ± 0.2 | 1.94 ± 0.2 | 0.70 |
Hypertension | 20 (89%) | 12 (88%) | 0.66 |
Diabetes mellitus | 8 (36%) | 5 (35%) | 0.81 |
Hypercholesterolemia | 17 (77%) | 10 (75%) | 0.51 |
Current smoker | 2 (9%) | 2 (12%) | 0.44 |
Ischemic cause (%) | 81% | 82% | 0.65 |
CRT-D | 4 (28.6%) | 7 (33.3%) | 0.21 |
Medical therapy | Â | Â | Â |
Ace-inhibitors or ARB | 10 (66.6%) | 14 (66.6%) | 0.81 |
Beta-blockers | 8 (53.3%) | 11 (52.3%) | 0.66 |
Spironolactone | 7 (46.7%) | 9 (42.8%) | 0.22 |
Loop diuretics | 13 (86.7%) | 18 (85.7) | 0.44 |
Statins | 9 (60.0%) | 14 (66.7%) | 0.32 |
Echocardiographic data | Â | Â | Â |
Left atrial area (cm2) | 26.9 ± 5.9 | 33.1 ± 6.6 | 0.02 |
Left atrial volume indexed (ml/m2) | 30.2 ± 9 | 41.1 ± 10.1 | 0.009 |
End-diastolic LV diameter (mm) | 57.3 ± 8.3 | 63.0 ± 8.0 | 0.01 |
LV mass index (g/m2) | 116.6 ± 31.3 | 118.3 ± 33.5 | 0.21 |
LV Ejection Fraction (%) | 26.5 ± 3.5 | 25.7 ± 4.3 | 0.15 |
Mitral E (cm/s) | 82.6 ± 33 | 99.4 ± 46 | <0.001 |
Mitral E/A ratio | 2.19 ± 1.1 | 3.66 ± 1.3 | <0.001 |
Sm (cm/s) | 5.0 ± 1.1 | 5.0 ± 1.2 | 0.81 |
Em (cm/s) | 6.6 ± 1.8 | 6.2 ± 1.8 | 0.24 |
E/Em (cm/s) | 12.6 ± 6.4 | 15.9 ± 7.9 | 0.01 |
Global PALS (%) | 16.9 ± 4.0 | 9.8 ± 4.2 | <0.001 |
4-chamber PALS (%) | 14.3 ± 3.8 | 8.0 ± 3.6 | <0.001 |
2-chamber PALS (%) | 18.0 ± 4.6 | 11.2 ± 4.5 | <0.001 |
Global TPLS (ms) | 445 ± 81 | 410 ± 78 | 0.09 |
Catheterization data | Â | Â | Â |
Heart rate (bpm) | 73.3 ± 15.3 | 76.0 ± 15.1 | 0.20 |
Systolic blood pressure (mmHg) | 118 ± 19 | 116 ± 21 | 0.28 |
Diastolic blood pressure (mmHg) | 79 ± 11 | 76 ± 13 | 0.27 |
Mean PAP (mmHg) | 21.8 ± 7.8 | 32.1 ± 9.9 | <0.001 |
PCWP (mmHg) | 13.1 ± 5.1 | 23.8 ± 7.4 | <0.001 |
CI therm (ml/min/m2) | 2.12 ± 0.7 | 2.13 ± 0.9 | 0.40 |
CI fick (ml/min/m2) | 1.99 ± 0.4 | 1.97 ± 0.4 | 0.42 |